Retreatment with nafarelin for recurrent endometriosis symptoms: efficacy, safety, and bone mineral density
- 1 June 1997
- journal article
- clinical trial
- Published by Elsevier in Fertility and Sterility
- Vol. 67 (6) , 1013-1018
- https://doi.org/10.1016/s0015-0282(97)81432-x
Abstract
No abstract availableKeywords
This publication has 11 references indexed in Scilit:
- Nafarelin therapy in endometriosis: Long-term effects on bone mineral densityAmerican Journal of Obstetrics and Gynecology, 1994
- Gonadotropin-releasing hormone analogues for the treatment of endometriosis: long-term follow-upFertility and Sterility, 1993
- A randomized double blind placebo controlled trial of the effects on bone metabolism of the combination of nafarelin acetate and norethisteroneClinical Endocrinology, 1992
- Gonadotropin-releasing hormone agonists and the skeletonFertility and Sterility, 1992
- Longitudinal precision of dual-energy X-ray absorptiometry in a multicenter studyJournal of Bone and Mineral Research, 1991
- Spinal Bone Loss and Ovulatory DisturbancesNew England Journal of Medicine, 1990
- THE EFFECTS OF NAFARELIN AND DANAZOL ON VERTEBRAL TRABECULAR BONE MASS IN PATIENTS WITH ENDOMETRIOSISClinical Endocrinology, 1990
- Reduced Bone Mass in Reproductive-Aged Women with Endometriosis*Journal of Clinical Endocrinology & Metabolism, 1989
- The Effect of a Gonadotropin-Releasing Hormone Agonist Analog (Nafarelin) on Bone MetabolismJournal of Clinical Endocrinology & Metabolism, 1988
- Administration of Nasal Nafarelin as Compared with Oral Danazol for EndometriosisNew England Journal of Medicine, 1988